Document Detail


Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent pancreatic cancer: comparison with integrated FDG-PET/non-contrast-enhanced CT and enhanced CT.
MedLine Citation:
PMID:  19949988     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: The purpose of this study is to evaluate the accuracy of 2-deoxy-2-[F-18]fluoro-D: -glucose-positron emission tomography (FDG-PET)/computed tomography (CT) with intravenous contrast for depiction of recurrent pancreatic cancer, compared with PET/non-enhanced CT and CT. PROCEDURE: Forty-five patients previously treated for pancreatic cancer underwent PET/CT for suspected recurrence. Lesion status was determined on the basis of histopathology and radiological imaging follow-up. RESULTS: Patient-based analysis showed that sensitivity, specificity, and accuracy of PET/contrast-enhanced CT were 91.7%, 95.2%, and 93.3%, respectively, whereas those of PET/non-enhanced CT were 83.3%, 90.5%, and 86.7%, respectively, and those of enhanced CT were 66.7%, 85.7%, and 75.6%, respectively. In 21 patients whom the final diagnosis was obtained from the histopathologic examination, those figures of PET/contrast-enhanced CT were 94.7%, 50.0%, and 90.4%, respectively. The sensitivity of PET/contrast-enhanced CT in detecting local recurrence, abdominal lymph node metastasis, and peritoneal dissemination were 83.3%, 87.5%, and 83.3%, respectively. CONCLUSION: PET/contrast-enhanced CT is an accurate modality for assessing recurrence of pancreatic cancer.
Authors:
Kazuhiro Kitajima; Koji Murakami; Erena Yamasaki; Yasushi Kaji; Mitsugi Shimoda; Keiichi Kubota; Narufumi Suganuma; Kazuro Sugimura
Related Documents :
10586018 - Endosonography in decision making and management of gastrointestinal endocrine tumors.
17268018 - 18f-fdg pet/ct in patients with suspected recurrent or metastatic well-differentiated t...
20808588 - Evaluation of shoulder disorders by 2-[f-18]-fluoro-2-deoxy-d-glucose positron emission...
19847358 - How to choose pet-ct or ct in the diagnosis and staging of lung cancer. practical exper...
15709668 - Design of a novel mri compatible manipulator for image guided prostate interventions.
8875408 - Improved centric phase encoding orders for three-dimensional magnetization-prepared mr ...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't     Date:  2009-12-01
Journal Detail:
Title:  Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging     Volume:  12     ISSN:  1860-2002     ISO Abbreviation:  Mol Imaging Biol     Publication Date:  2010 Aug 
Date Detail:
Created Date:  2010-08-02     Completed Date:  2010-11-10     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101125610     Medline TA:  Mol Imaging Biol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  452-9     Citation Subset:  IM    
Affiliation:
Department of Radiology, Dokkyo University School of Medicine, Mibu, Japan. kazu10041976@yahoo.co.jp
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Contrast Media / diagnostic use*
Female
Fluorodeoxyglucose F18 / diagnostic use*
Humans
Lymphatic Metastasis / radiography,  radionuclide imaging
Male
Middle Aged
Organ Specificity
Pancreatic Neoplasms / pathology,  radiography*,  radionuclide imaging*,  surgery
Positron-Emission Tomography*
Recurrence
Tomography, X-Ray Computed*
Chemical
Reg. No./Substance:
0/Contrast Media; 63503-12-8/Fluorodeoxyglucose F18

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  MR Imaging of Inflammation during Myelin-Specific T Cell-Mediated Autoimmune Attack in the EAE Mouse...
Next Document:  Molecular Imaging of the Translocator Protein (TSPO) in a Pre-Clinical Model of Breast Cancer.